AAA
NBIX icon

Affinity Asset Advisors’s Neurocrine Biosciences NBIX Stock Holding History

Affinity Asset Advisors’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-50,000
Closed -$5.53M – 108
2025
Q1 		$5.53M Buy
+50,000
New +$6.33M 0.53% 38
2024
Q1 		– Sell
-10,000
Closed -$1.32M – 111
2023
Q4 		$1.32M Buy
+10,000
New +$1.15M 0.24% 64

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Affinity Asset Advisors's NBIX Position: Q2 2025 in Review

Affinity Asset Advisors sold out of Neurocrine Biosciences (NBIX) in Q2 2025, closing a stake of 50,000 shares — an estimated $5.53M sold.

Affinity Asset Advisors first reported a position in NBIX in Q4 2023 and held it in 2 quarters. The position peaked at $5.53M in Q1 2025. 585 funds tracked by Wall St. Rank hold NBIX as of Q2 2025.

  • Affinity Asset Advisors reported no remaining Neurocrine Biosciences position as of Q2 2025 after selling out during the quarter.
  • Affinity Asset Advisors sold 50,000 Neurocrine Biosciences shares in Q2 2025, an estimated $5.53M.
  • Affinity Asset Advisors first reported a position in Neurocrine Biosciences in Q4 2023 and held it in 2 quarters.
  • Affinity Asset Advisors's Neurocrine Biosciences position peaked at $5.53M in Q1 2025.
  • 585 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2025.

Based on Affinity Asset Advisors's 13F filing for Q2 2025, filed 13 Aug 2025.